Project Description
Product Description
Paclitaxel is a biosynthetic anti-cancer drug. The mechanism of action is associated with the ability to stimulate the assembly of microtubules from dimeric tubulin molecules, to stabilize their structure by suppressing depolymerization and to inhibit dynamic reorganization in the interphase, which disrupts the mitotic function of the cell. In addition, paclitaxel induces the formation of abnormal clusters, or “bundles”, of microtubules throughout the cell cycle and causes the formation of multiple microtubule stars during mitosis. According to experimental data, it has mutagenic and embryotoxic properties, causes a decrease in reproductive function.
Benefits
Ovarian cancer.
– First-line therapy in combination with platinum preparations in patients with advanced ovarian cancer or with a residual tumor (more than 1 cm) after the initial laparotomy.
– Second-line therapy in patients with metastatic ovarian cancer after standard therapy, which did not lead to a positive result.
Breast cancer.
– Adjuvant therapy in patients with the presence of metastases in the lymph nodes after standard combined treatment;
– First-line therapy in patients with late-stage cancer or metastatic cancer after a relapse of the disease within 6 months after the start of adjuvant therapy, with the inclusion of anthracycline drugs, in the absence of indications for their use;
– First-line therapy in patients with late-stage cancer or metastatic breast cancer in combination with anthracycline drugs in the absence of contraindications for their use, or in combination with trastuzumab in patients with immunohistochemically confirmed 2+ or 3+ levels of HER-2 expression;
– Second-line therapy in patients with late-stage cancer or with metastatic cancer with the progression of the disease after combined chemotherapy. Previous therapy should include anthracycline drugs in the absence of contraindications for their use.
Contraindications
- Hypersensitivity to paclitaxel or any component included in the composition of the drug, especially macrogol glyceryltrinitrate (polyoxyethylene castor oil);
- The initial neutrophil content is less than 1500 / µl in patients with solid tumors;
- The initial or registered neutrophil content of less than 1000 / µl in patients with Kaposi’s sarcoma caused by AIDS;
- Concomitant serious uncontrolled infections in patients with Kaposi’s sarcoma;
- Pregnancy and breastfeeding;
Packing & Shipping
Why Choose Us & How to Order?
Located in China, if you purchase from us,we offer many additional convenient services, all of which cannot be easilly provided by other ingeredient products suppliers. Welcome to contact us to get FREE SAMPLE, COA and Nutrition Facts！
Hot Tags: Paclitaxel, Chinese manufacturers, suppliers, factory, wholesale, for sale, bulk
Leave A Comment